Findings seen over three months in men with low-grade prostate cancer, hypogonadism treated with radical prostatectomy ...
Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.
Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...
Although blood test reduces deaths by two for every 1,000 men screened, many could face unnecessary treatment ...
KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...
A comprehensive study reveals prostate cancer screening saves lives, reducing deaths by two per 1,000 men screened, but many ...
CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...
In a randomized clinical trial, Mass General Brigham researchers found testosterone replacement therapy also improved quality of life for men who had undergone radical prostatectomy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results